TY - JOUR
T1 - The mortality of COVID-19 in CML patients from 2020 until 2022
T2 - results from the EPICOVIDEHA survey
AU - el-Ashwah, Shaimaa
AU - Salmanton-García, Jon
AU - Bilgin, Yavuz M.
AU - Itri, Federico
AU - Žák, Pavel
AU - Weinbergerová, Barbora
AU - Verga, Luisa
AU - Omrani, Ali S.
AU - Silva, Maria Gomes da
AU - Szotkowski, Tomáš
AU - Marchetti, Monia
AU - Buquicchio, Caterina
AU - Nucci, Marcio
AU - Schönlein, Martin
AU - Farina, Francesca
AU - Besson, Caroline
AU - Prezioso, Lucia
AU - Nizamuddin, Summiya
AU - Dávila-Valls, Julio
AU - Martín-Pérez, Sonia
AU - Bonuomo, Valentina
AU - van Doesum, Jaap
AU - Tisi, Maria Chiara
AU - Passamonti, Francesco
AU - Méndez, Gustavo-Adolfo
AU - Meers, Stef
AU - Maertens, Johan
AU - López-García, Alberto
AU - Glenthøj, Andreas
AU - Bonnani, Matteo
AU - Rinaldi, Ikhwan
AU - Ormazabal-Vélez, Irati
AU - Labrador, Jorge
AU - Kulasekararaj, Austin
AU - Espigado, Ildefonso
AU - Demirkan, Fatih
AU - de Jonge, Nick
AU - Collins, Graham P.
AU - Calbacho, Maria
AU - Blennow, Ola
AU - Al-Khabori, Murtadha
AU - Adžić-Vukičević, Tatjana
AU - Arellano, Elena
AU - Mišković, Bojana
AU - Mladenović, Miloš
AU - Nordlander, Anna
AU - Ráčil, Zdeněk
AU - Ammatuna, Emanuele
AU - Cordoba, Raul
AU - Hersby, Ditte Stampe
AU - Gräfe, Stefanie
AU - Emarah, Ziad
AU - Hanakova, Michaela
AU - Sacchi, Maria Vittoria
AU - Ijaz, Marriyam
AU - Rahimli, Laman
AU - Nunes Rodrigues, Raquel
AU - Zambrotta, Giovanni Paolo Maria
AU - Marchesi, Francesco
AU - Cornely, Oliver A.
AU - Pagano, Livio
N1 - Publisher Copyright: © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
AB - Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates of hospitalization, intensive care unit (ICU) admissions, and mortality. In comparison to other haematological malignancy patients, individuals with chronic myeloid leukemia (CML) generally have better prognosis. This study, conducted using a large haematological malignancy patient database (EPICOVIDEHA), demonstrated that the majority of CML patients experienced mild infections. The decline in severe and critical infections over the years can largely be attributed to the widespread administration of vaccinations and the positive response they elicited. Notably, the mortality rate among CML patients was low and exhibited a downward trend in subsequent years. Importantly, our analysis provided confirmation of the effectiveness of vaccinations in CML patients.
KW - COVID-19
KW - Chronic myeloid leukemia
KW - SARS-CoV-2
KW - neoplasia
KW - tirosine kinase inhibitor
KW - vaccines
UR - http://www.scopus.com/inward/record.url?scp=85176920648&partnerID=8YFLogxK
U2 - https://doi.org/10.1080/10428194.2023.2280886
DO - https://doi.org/10.1080/10428194.2023.2280886
M3 - Article
C2 - 37966980
SN - 1042-8194
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
ER -